Thus, the oncogenic BCR-ABL protein in CML enhances cell survival at least in part through its inhibitory effect on CCN3, resulting in reduced apoptosis and enhanced cell growth. This evidence concerns the gene CCN3 and chronic myelogenous leukemia, BCR-ABL1 positive.